Do Analysts Agree Monday on Homology Medicines Inc (FIXX) Stock's Target Price?

Monday, February 05, 2024 02:43 PM | InvestorsObserver Analysts

Mentioned in this article

Do Analysts Agree Monday on Homology Medicines Inc (FIXX) Stock's Target Price?

InvestorsObserver is giving Homology Medicines Inc (FIXX) an Analyst Rating Rank of 5, meaning FIXX is ranked higher by analysts than 5% of stocks. The average price target for FIXX is $4.25 and analyst’s rate the stock as a Hold.

Wall Street analysts are rating FIXX a Hold today. Find out what this means to you and get the rest of the rankings on FIXX!

See Full FIXX Report

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers. InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With Homology Medicines Inc Stock Today?

Homology Medicines Inc (FIXX) stock is unmoved -0.57% while the S&P 500 has fallen -0.1% as of 2:41 PM on Monday, Feb 5. FIXX is unchanged $0.00 from the previous closing price of $0.70 on volume of 274,307 shares. Over the past year the S&P 500 is up 20.49% while FIXX has fallen -56.25%. FIXX lost -$2.27 per share the over the last 12 months. Click Here to get the full Stock Report for Homology Medicines Inc stock.